Recruiting TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts NCT03816319 Conditions Anemia, Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, +16 more Locations Moffitt Cancer Center — Tampa, Florida, United States Northwestern University — Chicago, Illinois, United States Ohio State University Comprehensive Cancer Center — Columbus, Ohio, United States VCU Massey Comprehensive Cancer Center — Richmond, Virginia, United States View more locations Show fewer locations Loading locations... View Trial Details
Recruiting Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes NCT06484062 Conditions Acute Myeloid Leukemia, Bone Marrow Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +18 more Locations Yale University — New Haven, Connecticut, United States Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia, United States University of Chicago Comprehensive Cancer Center — Chicago, Illinois, United States UC Comprehensive Cancer Center at Silver Cross — New Lenox, Illinois, United States View all 22 locations View more locations Show fewer locations Loading locations... View Trial Details
